Compound could help diabetic patients walk tightrope between heperglycemia, hypoglycemia.
A pharmaceutical company is proceeding with clinical testing of a new compound that could make it easier for diabetic patients to maintain good control of blood-sugar levels. The compound, a peptide called amylin, appears to lessen wild fluctuations in blood-glucose levels by slowing the rate of gastric emptying and moderating the amount of postprandial glucose. Fran Lowry interviewed the researcher who discovered the peptide.
Lowry
F
F
D000682:Amyloid / Q000627:therapeutic use*; D001786:Blood Glucose / Q000032:analysis / Q000378:metabolism; D003920:Diabetes Mellitus / Q000097:blood / Q000188:drug therapy; D005746:Gastric Emptying / Q000187:drug effects; D006801:Humans; D006943:Hyperglycemia / Q000517:prevention & control; D007003:Hypoglycemia / Q000517:prevention & control; D058228:Islet Amyloid Polypeptide
D000682:Amyloid; D001786:Blood Glucose; D058228:Islet Amyloid Polypeptide